Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Neurofascin as a novel target for autoantibody-mediated axonal injury.

Mathey EK, Derfuss T, Storch MK, Williams KR, Hales K, Woolley DR, Al-Hayani A, Davies SN, Rasband MN, Olsson T, Moldenhauer A, Velhin S, Hohlfeld R, Meinl E, Linington C.

J Exp Med. 2007 Oct 1;204(10):2363-72. Epub 2007 Sep 10.

2.

Neurofascin 186 specific autoantibodies induce axonal injury and exacerbate disease severity in experimental autoimmune encephalomyelitis.

Lindner M, Ng JK, Hochmeister S, Meinl E, Linington C.

Exp Neurol. 2013 Sep;247:259-66. doi: 10.1016/j.expneurol.2013.05.005. Epub 2013 May 18.

PMID:
23688679
3.

MOG-induced experimental autoimmune encephalomyelitis in the rat species triggers anti-neurofascin antibody response that is genetically regulated.

Flytzani S, Guerreiro-Cacais AO, N'diaye M, Lindner M, Linington C, Meinl E, Stridh P, Jagodic M, Olsson T.

J Neuroinflammation. 2015 Oct 29;12:194. doi: 10.1186/s12974-015-0417-2.

4.
5.

Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies.

Koike H, Kadoya M, Kaida KI, Ikeda S, Kawagashira Y, Iijima M, Kato D, Ogata H, Yamasaki R, Matsukawa N, Kira JI, Katsuno M, Sobue G.

J Neurol Neurosurg Psychiatry. 2017 Jun;88(6):465-473. doi: 10.1136/jnnp-2016-314895. Epub 2017 Jan 10.

PMID:
28073817
6.

Autoantibodies in neuroimmunological diseases; relevance of fine specificity.

Kusunoki S.

Exp Neurol. 2013 Dec;250:219-20. doi: 10.1016/j.expneurol.2013.10.009. Epub 2013 Oct 10.

PMID:
24120752
7.

Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis.

Lonigro A, Devaux JJ.

Brain. 2009 Jan;132(Pt 1):260-73. doi: 10.1093/brain/awn281. Epub 2008 Oct 25.

PMID:
18953054
8.

Antibodies to neurofascin exacerbate adoptive transfer experimental autoimmune neuritis.

Yan W, Nguyen T, Yuki N, Ji Q, Yiannikas C, Pollard JD, Mathey EK.

J Neuroimmunol. 2014 Dec 15;277(1-2):13-7. doi: 10.1016/j.jneuroim.2014.09.012. Epub 2014 Sep 18.

PMID:
25262157
9.

Nodal proteins are target antigens in Guillain-Barré syndrome.

Devaux JJ, Odaka M, Yuki N.

J Peripher Nerv Syst. 2012 Mar;17(1):62-71. doi: 10.1111/j.1529-8027.2012.00372.x.

PMID:
22462667
10.

Untapped targets in multiple sclerosis.

Meinl E.

J Neurol Sci. 2011 Dec;311 Suppl 1:S12-5.

PMID:
22206760
11.

Prevalence of neurofascin-155 antibodies in patients with multiple sclerosis.

Stich O, Perera S, Berger B, Jarius S, Wildemann B, Baumgartner A, Rauer S.

J Neurol Sci. 2016 May 15;364:29-32. doi: 10.1016/j.jns.2016.03.004. Epub 2016 Mar 3.

PMID:
27084211
12.

Neurofascin as a target for autoantibodies in peripheral neuropathies.

Ng JK, Malotka J, Kawakami N, Derfuss T, Khademi M, Olsson T, Linington C, Odaka M, Tackenberg B, Prüss H, Schwab JM, Harms L, Harms H, Sommer C, Rasband MN, Eshed-Eisenbach Y, Peles E, Hohlfeld R, Yuki N, Dornmair K, Meinl E.

Neurology. 2012 Dec 4;79(23):2241-8. doi: 10.1212/WNL.0b013e31827689ad. Epub 2012 Oct 24.

13.

Alteration of the extracellular matrix interferes with raft association of neurofascin in oligodendrocytes. Potential significance for multiple sclerosis?

Maier O, van der Heide T, van Dam AM, Baron W, de Vries H, Hoekstra D.

Mol Cell Neurosci. 2005 Feb;28(2):390-401.

PMID:
15691718
14.

B- and T-cell responses in multiple sclerosis: novel approaches offer new insights.

Hohlfeld R, Meinl E, Dornmair K.

J Neurol Sci. 2008 Nov 15;274(1-2):5-8. doi: 10.1016/j.jns.2008.07.006. Epub 2008 Aug 15. Review.

PMID:
18707694
15.

Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury.

Derfuss T, Linington C, Hohlfeld R, Meinl E.

J Mol Med (Berl). 2010 Aug;88(8):753-61. doi: 10.1007/s00109-010-0632-3. Epub 2010 May 6. Review.

PMID:
20445955
16.

Identification of autoantibodies associated with myelin damage in multiple sclerosis.

Genain CP, Cannella B, Hauser SL, Raine CS.

Nat Med. 1999 Feb;5(2):170-5.

PMID:
9930864
17.

In vitro and in vivo models of multiple sclerosis.

van der Star BJ, Vogel DY, Kipp M, Puentes F, Baker D, Amor S.

CNS Neurol Disord Drug Targets. 2012 Aug;11(5):570-88. Review.

PMID:
22583443
18.

Disruption of neurofascin localization reveals early changes preceding demyelination and remyelination in multiple sclerosis.

Howell OW, Palser A, Polito A, Melrose S, Zonta B, Scheiermann C, Vora AJ, Brophy PJ, Reynolds R.

Brain. 2006 Dec;129(Pt 12):3173-85. Epub 2006 Oct 14.

PMID:
17041241
19.

Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy.

Delmont E, Manso C, Querol L, Cortese A, Berardinelli A, Lozza A, Belghazi M, Malissart P, Labauge P, Taieb G, Yuki N, Illa I, Attarian S, Devaux JJ.

Brain. 2017 Jul 1;140(7):1851-1858. doi: 10.1093/brain/awx124.

PMID:
28575198
20.

[Neurofascin: a novel target for combined central and peripheral demyelination].

Kawamura N.

Rinsho Shinkeigaku. 2014;54(12):978-80. doi: 10.5692/clinicalneurol.54.978. Review. Japanese.

PMID:
25672685

Supplemental Content

Support Center